Skip to main
MPLT

MPLT Stock Forecast & Price Target

MPLT Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 78%
Buy 22%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MapLight Therapeutics is well-positioned in the market with its innovative discovery platform and multiple promising drug candidates, making it a strong investment for those with a long-term outlook. The company's expected sales targets and positive financial outlook add to its appeal, despite potential competition in the market. With the demand for effective and convenient treatments for central nervous system disorders on the rise, MapLight Therapeutics has the potential for significant growth and success in the future.

Bears say

MapLight Therapeutics is a clinical-stage biopharmaceutical company with a unique approach to targeting central nervous system disorders. While the potential of ML-007C-MA is promising, success is far from guaranteed and the company faces stiff competition in the market. Furthermore, the potential for ML-004 to treat ASD, while intriguing, is still in early stages and has no guarantee of success, making it a risky investment.

MPLT has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 78% of analysts recommend a Strong Buy, 22% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MapLight Therapeutics Inc (MPLT) Forecast

Analysts have given MPLT a Strong Buy based on their latest research and market trends.

According to 9 analysts, MPLT has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MapLight Therapeutics Inc (MPLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.